

## EVA Categorisation of antibiotics for use in animals for prudent and responsible use



The Antimicrobial Advice Ad Hoc Expert Group (AMEG) has categorised antibiotics based on the potential consequences to public health of increased antimicrobial resistance when used in animals and the need for their use in veterinary medicine.

The categorisation is intended as a tool to support decision-making by veterinarians on which antibiotic to use.

**Veterinarians are encouraged to check the AMEG categorisation before prescribing any antibiotic for animals in their care.** The AMEG categorisation does not replace treatment guidelines, which also need to take account of other factors such as supporting information in the Summary of Product Characteristics for available medicines, constraints around use in food-producing species, regional variations in diseases and antibiotic resistance, and national prescribing policies.



 as always, should be used prudently, only when medically needed

> You Tube

 $(\mathcal{O}) \rightarrow \mathcal{O}$ 

 should be considered only when there are no antibiotics in Category D that could be clinically effective

for some veterinary indications, there are no

alternatives belonging to Category D

## For antibiotics in all categories

- unnecessary use, overly long treatment periods, and under-dosing should be avoided
- group treatment should be restricted to situations where individual treatment is not feasible
- check out the European Commission's guideline on prudent use of antibiotics in animals: https://bit.ly/2s7LUF2

AMEG is the acronym for EMA's Antimicrobial Advice Ad Hoc Expert Group. It brings together experts from both human and veterinary medicine. They work together to provide guidance on the impact on public health of the use of antibiotics in animals.



Full AMEG report: https://bit.ly/30ZEuRi

			lasses for veterinary use in		
A	Amdinopenicillins mecillinam pivmecillinam Ketolides telithromycin Monobactams aztreonam	Carbapenems meropenem doripenem Lipopeptides daptomycin Oxazolidinones linezolid	Drugs used solely to treat tuberculosis or other mycobacterial diseases isoniazid ethambutol pyrazinamide ethionamide	Glycopeptides vancomycin Glycylcyclines tigecycline Phosphonic acid derivates fosfomycin	AVOID
	Rifamycins (except rifaximin) rifampicin Carboxypenicillin and ureidopenicillin, including combinations with beta lactamase inhibitors piperacillin-tazobactam	Riminofenazines clofazimine Sulfones dapsone Streptogramins pristinamycin virginiamycin	Other cephalosporins and penems (ATC code J01DI), including combinations of 3rd-generation cephalosporins with beta lactamase inhibitors ceftobiprole ceftaroline ceftolozane-tazobactam faropenem	Pseudomonic acids mupirocin Substances newly authorised in human medicine following publication of the AMEG categorisation to be determined	
B	Cephalosporins, 3rd- and 4th-generation, with the exception of combinations with β-lactamase inhibitors cefoperazone cefovecin cefquinome ceftiofur	<b>Polymyxins</b> colistin polymyxin B	Quinolones: fluoroquinolones and cinoxacin danofloxacin difloxacin enrofloxacin flumequine ibafloxacin	l other quinolones marbofloxacin norfloxacin orbifloxacin oxolinic acid pradofloxacin	RESTRICT
С	Aminoglycosides (except spectinomycin) amikacin apramycin dihydrostreptomycin framycetin gentamicin kanamycin neomycin paromomycin streptomycin tobramycin	Aminopenicillins, in combination with beta lactamase inhibitors amoxicillin + clavulanic acid ampicillin + sulbactam Cephalosporins, 1st- and 2nd-generation, and cephamycins cefacetrile cefadroxil cefalexin cefalonium cefalotin cefapirin	Amphenicols chloramphenicol florfenicol thiamphenicol Lincosamides clindamycin lincomycin pirlimycin Pleuromutilins tiamulin	Macrolides erythromycin gamithromycin oleandomycin spiramycin tildipirosin tilmicosin tulathromycin tylosin tylvalosin Rifamycins: rifaximin only rifaximin	CAUTION
D	Aminopenicillins, without   beta-lactamase inhibitors   amoxicillin   ampicillin   metampicillin   Tetracyclines   chlortetracycline   oxytetracycline   oxytetracycline   tetracycline	cefapirin cefazolin Aminoglycosides: spectinomycin only spectinomycin Anti-staphylococcal penicillins (beta-lactamase-resistant penicillins) cloxacillin dicloxacillin nafcillin oxacillin	valnemulin Sulfonamides, dihydrofolate redu inhibitors and combinations formosulfathiazole phthalylsulfathiazole sulfacetamide sulfachorpyridazine sulfaclozine sulfadiazine sulfadimethoxine sulfadimidine sulfadoxine sulfafurazole sulfaguanidine		PRUDENCE
	Natural, narrow-spectrum penicillins (beta lactamase-sensitive penicillins) pheneticillin   benzathine benzylpenicillin pheneticillin   benzathine phenoxymethylpenicillin phenoxymethylpenicillin   benzylpenicillin phenoxymethylpenicillin   penethamate hydriodide procaine benzylpenicillin		Cyclic polypeptides bacitracin Steroid antibacterials fusidic acid	Nitroimidazoles metronidazole Nitrofuran derivatives furaltadone furazolidone	

## **Other factors to consider**

The **route of administration** should be taken into account alongside the categorisation when prescribing antibiotics. The list below suggests routes of administration and types of formulation ranked from the lowest to the highest estimated impact on antibiotic resistance.

Local individual treatment (e.g. udder injector, eye or ear drops) Parenteral individual treatment (intravenously, intramuscularly, subcutaneously) Oral individual treatment (i.e. tablets, oral bolus) Injectable group medication (metaphylaxis), only if appropriately justified Oral group medication via drinking water/milk replacer (metaphylaxis), only if appropriately justified Oral group medication via feed or premixes (metaphylaxis), only if appropriately justified





Full AMEG report: https://bit.ly/30ZEuRi

